表紙
市場調查報告書

藥物濫用抑制劑:開發平台分析

Abuse Deterrents - Pipeline Analytics, H1 2019

出版商 GervanoRA Data Services LLP 商品編碼 813723
出版日期 內容資訊 英文 188 Pages
訂單完成後即時交付
價格
藥物濫用抑制劑:開發平台分析 Abuse Deterrents - Pipeline Analytics, H1 2019
出版日期: 2019年03月26日內容資訊: 英文 188 Pages
簡介

本報告提供全球藥物中毒、濫用抑制劑的市場相關分析,未滿足需求和市場機會,整體市場趨勢的成果值、預測值,臨床實驗的發展情形,各產品類型詳細趨勢,主要企業的概要和SWOT分析,現在臨床實驗中的產品與今後的預測,參與臨床實驗的企業、大學、研究機關的一覽等資訊彙整,為您概述為以下內容。

第1章 簡介

第2章 摘要整理

第3章 興奮劑中毒 (古柯鹼,甲基安非他命) 市場概要

  • 興奮劑中毒概要
  • 全球市場方案
  • 興奮劑中毒的流行病學
  • 流行病學的預測
  • 興奮劑中毒:建議的治療方法

第4章 興奮劑濫用概要

  • 興奮劑的濫用與抑制
  • 興奮劑濫用的促進因素
  • 興奮劑濫用的影響與症狀
  • 興奮劑濫用的目前治療方法
  • 興奮劑濫用:健康、社會、經濟的影響

第5章 濫用抑制劑市場上資本交易概要

  • 資本交易趨勢 (企業合併、收購 (M&A),事業合作)
    • 合作協定
    • 許可證協定
    • 看護契約、調停
    • 資金融資、契約
    • 事業聯盟
    • 企業收購

第6章 興奮劑濫用抑制劑市場:近幾年趨勢與技術

  • 興奮劑濫用抑制劑的處方策略
  • 興奮劑濫用抑制劑的處方技術
  • 濫用物質的國際標準
  • 興奮劑濫用的治療相關,醫療上的未滿足需求和差距
  • 興奮劑濫用:全世界的趨勢和法規的整備
  • 興奮劑濫用抑制劑:處方上的限制

第7章 古柯鹼、甲基安非他命濫用抑制劑:開發平台分析

  • 臨床實驗中的治療藥:各階段
    • 第二階段的分子
    • 第一階段的分子
    • 前臨床階段的分子
    • 早期R&D階段的分子
    • 惰性分子
  • 開發平台分析:各地區
  • 開發平台分析:各給藥途徑
  • 開發平台分析:各大學、企業、研究機關

第8章 興奮劑濫用抑制劑的開發平台分析

  • 開發平台分析:各臨床實驗階段
    • 核准前分子
    • 第三階段的分子
    • 第二階段的分子
    • 第一階段的分子
    • 前臨床分子
    • 早期R&D (藥物研發) 階段的分子
  • 開發平台分析:各地區
  • 開發平台分析:各給藥途徑
  • 開發平台分析:各類藥物
  • 開發平台分析:各作用機制
  • 開發平台分析:各大學、企業、研究機關

第9章 估計的藥物認證的時間軸

  • 分析方法
  • 興奮劑濫用抑制劑的上市時期分析
  • 古柯鹼、甲基安非他命濫用抑制劑的上市時期分析
    • 美國的情況 (FDA)
    • 歐洲的情況 (EMA/國際組織)

第10章 臨床實驗概況

  • 古柯鹼、甲基安非他命濫用抑制劑
    • 開發平台分析:各臨床實驗成果
    • 現在進行中的臨床實驗:概要
    • 計劃中臨床實驗:概要
    • 近幾年完成的臨床實驗
  • 興奮劑濫用抑制劑
    • 開發平台分析:各臨床實驗成果
    • 計劃中臨床實驗:概要
    • 近幾年完成的臨床實驗
  • 中止的計劃

第11章 現在、未來的競爭環境

  • 新加入企業
  • 新加入企業的簡介,和藥物的概要及里程碑
    • 古柯鹼、甲基安非他命濫用抑制劑的情況
    • 興奮劑濫用抑制劑的情況
  • 大學、研究機關

第12章 簡稱一覽

目錄
Product Code: GERPH1311

GervanoRA's pipeline analysis and opportunity assessment report "Abuse Deterrents: Pipeline Analytics, H1 2019" analyzed and assessed the pipeline molecules for Abuse Deterrents along with Stimulant Addiction (Cocaine and Methamphetamine) Market Overview by considering the global scenarios, epidemiology and proposed treatments for the Stimulant Addiction. The report also provides information related to Stimulant Abuse and Deterrence, factors affecting, treatments and impact on Health, Social and Economy through Stimulant Abuse. The Report also focuses on the global trends, recent developments and technologies like the formulation strategies and formulation technologies. For a good understanding about the report we have provided the Pipeline Analysis for Abuse Deterrents based on two segments- Cocaine and Methamphetamine Drug Abuse Deterrent and Stimulant Drug Abuse Deterrent. We have in turn segmented the Chapter with respect to the Highest Stage of development, Geography, Route of Administration, Drug Class and Mechanism of Action.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Unmet needs and Opportunities
  • Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
  • Estimated Pipeline Drug Approval Time lines
  • Clinical Trials Summary
  • Current and Future Competitive Landscape
  • Key Company Profiles with SWOT Analysis
  • Pipeline Drug Descriptions along with Development milestones (Past and Future)
  • University Pipeline Molecules & In-Licensing/Out Licensing Opportunities.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. UPCOMING AND OTHER AVAILABLE PIPELINE ANALYSIS REPORTS
  • 1.4. ABOUT US: GERVANORA DATA SERVICES

2. EXECUTIVE SUMMARY

  • 2.1. REPORTS MAJOR FINDINGS
  • 2.2. KEY PIPELINE EVENTS 2018 TO 2034

3. STIMULANT ADDICTION (COCAINE & METHAMPHETAMINE) MARKET OVERVIEW

  • 3.1. STIMULANT ADDICTION OVERVIEW
  • 3.2. STIMULANT ADDICTION GLOBAL SCENARIOS
  • 3.3. STIMULANT ADDICTION EPIDEMIOLOGY
  • 3.4. EPIDEMIOLOGY FORECAST
    • 3.4.1. FORECAST METHODOLOGY AND ASSUMPTION
    • 3.4.2. PROBABILISTIC EPIDEMIOLOGY FORECAST
  • 3.5. STIMULANT ADDICTION PROPOSED TREATMENTS

4. STIMULANT ABUSE OVERVIEW

  • 4.1. STIMULANT ABUSE AND DETERRENCE
  • 4.2. FACTORS AFFECTING ON STIMULANT ABUSE
  • 4.3. EFFECTS AND SYMPTOMS OF STIMULANT ABUSE
  • 4.4. CURRENT TREATMENTS OF STIMULANT ABUSE
  • 4.5. STIMULANT ABUSE - IMPACT ON HEALTH, SOCIAL AND ECONOMY

5. ABUSE DETERRENT DEALS OVERVIEW

  • 5.1. DEALS (MERGERS/ ACQUISITIONS / COLLABORATIONS)
    • 5.1.1. COLLABORATION AGREEMENTS
    • 5.1.2. LICENSING AGREEMENTS
    • 5.1.3. TERMINATION AGREEMENTS AND SETTLEMENTS
    • 5.1.4. FUNDING & CONTRACTS
    • 5.1.5. PARTNERSHIPS
    • 5.1.6. ACQUISITIONS

6. STIMULANT ABUSE DETERRENTS-RECENT DEVELOPMENTS AND TECHNOLOGIES

  • 6.1. STIMULANT ABUSE DETERRENT FORMULATION STRATEGIES
  • 6.2. STIMULANT ABUSE DETERRENT FORMULATION TECHNOLOGIES
  • 6.3. INTERNATIONAL GUIDELINES FOR ABUSABLE SUBSTANCES
  • 6.4. UNMET MEDICAL NEEDS AND GAPS IN THE TREATMENT OF STIMULANT ABUSE
  • 6.5. STIMULANT ABUSE GLOBAL TRENDS AND REGULATORY DEVELOPMENTS
  • 6.6. LIMITATIONS OF STIMULANT ABUSE DETERRENT FORMULATIONS

7. PIPELINE ANALYSIS OF COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT

  • 7.1. THERAPEUTICS UNDER DEVELOPMENT BY STAGE OF DEVELOPMENT
    • 7.1.1. PHASE II MOLECULES
    • 7.1.2. PHASE I MOLECULES
    • 7.1.3. PRECLINICAL MOLECULES
    • 7.1.4. EARLY R&D MOLECULES
    • 7.1.5. INACTIVE MOLECULES
  • 7.2. PIPELINE ANALYSIS BY GEOGRAPHY
  • 7.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
  • 7.4. PIPELINE ANALYSIS BY COMPANIES, UNIVERSITIES & INSTITUTES

8. PIPELINE ANALYSIS OF STIMULANT DRUG ABUSE DETERRENT

  • 8.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT
    • 8.1.1. PRE-REGISTRATION (FILED) MOLECULES
    • 8.1.2. PHASE III MOLECULES
    • 8.1.3. PHASE II MOLECULES
    • 8.1.4. PHASE I MOLECULES
    • 8.1.5. PRECLINICAL MOLECULES
    • 8.1.6. EARLY R&D (DISCOVERY) MOLECULES
  • 8.2. PIPELINE ANALYSIS BY GEOGRAPHY
  • 8.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
  • 8.4. PIPELINE ANALYSIS BY DRUG CLASS
  • 8.5. PIPELINE ANALYSIS BY MECHANISM OF ACTION
  • 8.6. PIPELINE ANALYSIS BY COMPANIES, UNIVERSITIES & INSTITUTES

9. ESTIMATED DRUG APPROVAL TIMELINES

  • 9.1. METHODOLOGY
  • 9.2. STIMULANT DRUG ABUSE DETERRENT LAUNCH ANALYTICS
    • 9.2.1. UNITED STATES (FDA) ESTIMATIONS
    • 9.2.2. EX-UNITED STATES (EMA AND INTERNATIONAL) ESTIMATIONS
  • 9.3. COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT LAUNCH ANALYTICS
    • 9.3.1. UNITED STATES (FDA) ESTIMATIONS
    • 9.3.2. EX-UNITED STATES (EMA AND INTERNATIONAL) ESTIMATIONS

10. CLINICAL TRIAL SUMMARY

  • 10.1. COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT
    • 10.1.1. PIPELINE ANALYSIS BY CLINICAL TRIAL RESULTS
    • 10.1.2. ONGOING CLINICAL TRIALS SUMMARY
    • 10.1.3. PLANNED CLINICAL TRIAL SUMMARY
    • 10.1.4. RECENTLY COMPLETED CLINICAL TRIALS
  • 10.2. STIMULANT DRUG ABUSE DETERRENT
    • 10.2.1. PIPELINE ANALYSIS BY CLINICAL TRIAL RESULTS
    • 10.2.2. PLANNED CLINICAL TRIAL SUMMARY
    • 10.2.3. RECENTLY COMPLETED TRIALS
  • 10.3. WITHDRAWN AND DISCONTINUED PROJECTS

11. CURRENT AND FUTURE COMPETITIVE LANDSCAPE

  • 11.1. EMERGING COMPANIES
  • 11.2. EMERGING COMPANY PROFILES WITH DRUG DESCRIPTIONS AND MILESTONES
    • 11.2.1. COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT EMERGING COMPANIES
    • 11.2.2. STIMULANT DRUG ABUSE DETERRENT EMERGING COMPANIES
  • 11.3. UNIVERSITIES AND INSTITUTES

12. ABBREVIATIONS

LIST OF TABLES

  • TABLE 1: METHAMPHETAMINE V/S COCAINE
  • TABLE 2: ILLICIT DRUG USERS EPIDEMIOLOGY (2016), FORECAST (2017-2025)
  • TABLE 3: STIMULANT USERS EPIDEMIOLOGY (2016), FORECAST (2017-2025)
  • TABLE 4: COCAINE USERS EPIDEMIOLOGY (2016), FORECAST (2017-2025)
  • TABLE 5: METHAMPHETAMINE USERS EPIDEMIOLOGY (2016), FORECAST (2017-2025)
  • TABLE 6: COLLABORATION AGREEMENTS, 2000-2018
  • TABLE 7: LICENSING AGREEMENTS, 2013-2018
  • TABLE 8: TERMINATION AGREEMENTS
  • TABLE 9: FUNDING AND CONTRACTS
  • TABLE 10: PARTNERSHIPS DEALS
  • TABLE 11: ACQUISITION DEALS
  • TABLE 12: STAGE OF DEVELOPMENT V/S FORMULATION STRATEGIES
  • TABLE 13: MOLECULES BELONGING TO TYPE 3 FORMULATION STRATEGY
  • TABLE 14: MOLECULES BELONGING TO TYPE 2 FORMULATION STRATEGY
  • TABLE 15: MOLECULE BELONGING TO TYPE 1 FORMULATION STRATEGY
  • TABLE 16: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT PHASE II PIPELINE MOLECULES
  • TABLE 17: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT PHASE I PIPELINE MOLECULES
  • TABLE 18: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT PRECLINICAL STAGE PIPELINE MOLECULES
  • TABLE 19: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT EARLY R&D PIPELINE MOLECULES
  • TABLE 20: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT INACTIVE PIPELINE MOLECULES
  • TABLE 21: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
  • TABLE 22: PRE-REGISTRATION (FILED) MOLECULES IN THE STIMULANT DRUG ABUSE PIPELINE
  • TABLE 23: PHASE III MOLECULES IN THE STIMULANT DRUG ABUSE PIPELINE
  • TABLE 24: PHASE II MOLECULES IN THE STIMULANT DRUG ABUSE PIPELINE
  • TABLE 25: PHASE I MOLECULES IN THE STIMULANT DRUG ABUSE PIPELINE
  • TABLE 26: PRECLINICAL MOLECULES IN THE STIMULANT DRUG ABUSE PIPELINE
  • TABLE 27: EARLY R&D MOLECULES IN THE STIMULANT DRUG ABUSE PIPELINE
  • TABLE 28: LIST OF COMPANIES WITH PIPELINE MOLECULES BY STAGE OF DEVELOPMENT
  • TABLE 29: LIST OF UNIVERSITIES AND INSTITUTES WITH PIPELINE MOLECULES
  • TABLE 30: STIMULANT DRUG ABUSE DETERRENT LAUNCH ANALYTICS, US APPROVAL
  • TABLE 31: STIMULANT DRUG ABUSE DETERRENT LAUNCH ANALYTICS, EX US APPROVAL
  • TABLE 32: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT LAUNCH ANALYTICS, US APPROVAL
  • TABLE 33: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT LAUNCH ANALYTICS, EX US APPROVAL
  • TABLE 34: MN-166 (IBUDILAST) PHASE II CLINICAL TRIAL STUDY DESIGN
  • TABLE 35: SYN117 (NEPICASTAT) PHASE II CLINICAL TRIAL STUDY DESIGN
  • TABLE 36: MEASURED VALUE FOR PRIMARY MEASURE- ABSTINENCE
  • TABLE 37: MEASURED VALUE FOR SECONDARY MEASURE- REDUCTION IN USE
  • TABLE 38: ONGOING PHASE II CLINICAL TRIALS
  • TABLE 39: ORADUR-METHYLPHENIDATE ER PHASE III CLINICAL TRIALS STUDY DESIGN
  • TABLE 40: HLD200 PHASE III CLINICAL TRIALS STUDY DESIGN
  • TABLE 41: HLD200 SECOND PIVOTAL PHASE III CLINICAL TRIALS STUDY DESIGN
  • TABLE 42: HLD100 PHASE II TRIAL RESULTS
  • TABLE 43: RBP-8000 PHASE II CLINICAL TRIALS STUDY DESIGN
  • TABLE 44: LIST OF UNIVERSITIES AND INSTITUTES

LIST OF FIGURES

  • FIGURE 1: KEY PIPELINE EVENTS, COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT, 2021-2023
  • FIGURE 2: KEY PIPELINE EVENTS, COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT, 2024-2028
  • FIGURE 3: KEY PIPELINE EVENTS, STIMULANT DRUG ABUSE DETERRENT, 2018-2034
  • FIGURE 4: COCAINE USE TRENDS, US, 2002-2016
  • FIGURE 5: COCAINE USE TRENDS, CANADA, 2004-2009
  • FIGURE 6: RELATIVE COMPARISION IN PREVALENCE OF COCAINE AND METHAMPHETAMINE DRUG USE, 2009-2013
  • FIGURE 7: COMPARISION OF COCAINE USERS BY AGE GROUP, 2015-2016
  • FIGURE 8: COMPARISION OF METHAMPHETAMINE USERS BY AGE GROUP, 2015-2016
  • FIGURE 9: COCAINE USE, 2015-2016
  • FIGURE 10: ILLICIT DRUG USERS, US, 2010-2016
  • FIGURE 11: PREVALENCE OF COCAINE USE, AGE GROUP, CANADA, 2008-2015
  • FIGURE 12: ILLICIT DRUG USERS AGED 12 AND OLDER; FORECAST (2017-2025)
  • FIGURE 13: STIMULANT USERS AGED 12 AND OLDER; FORECAST (2017-2025)
  • FIGURE 14: COCAINE USERS AGED 12 AND OLDER; FORECAST (2017-2025)
  • FIGURE 15: METHAMPHETAMINE USERS AGED 12 AND OLDER; FORECAST (2017-2025)
  • FIGURE 16: PHARMACOLOGICAL TREATMENT OPTIONS FOR STIMULANT ADDICTION
  • FIGURE 17: DEAL ACTIVITY, CNS STIMULANTS AND OPIOIDS
  • FIGURE 18: STRATEGIES FOR STIMULANT ABUSE DETERRENT FORMULATION
  • FIGURE 19: ANNUAL PREVALENCE AND NUMBER OF ILLICIT DRUG USERS AT THE GLOBAL LEVEL, 2010
  • FIGURE 20: ILLICIT DRUG USE AT THE GLOBAL LEVEL, 2008
  • FIGURE 21: COMPARISION BETWEEN FEMALE AND MALE USERS ATTRIBUTABLE TO DRUG USE DISORDERS, 2005 AND 2015
  • FIGURE 22: DALY'S COMPARISION BETWEEN FEMALE AND MALE USERS ATTRIBUTABLE TO DRUG USE DISORDERS, 2005 AND 2015
  • FIGURE 23: ANNUAL PREVALENCE OF THE USE OF COCAINE AND METHAMPHETAMINE BY REGION AND GLOBALLY, 2015
  • FIGURE 24: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
  • FIGURE 25: STIMULANT DRUG ABUSE DETERRENT PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT- COMPANIES
  • FIGURE 26: STIMULANT DRUG DETERRENT PIPELINE ANALYSIS BY GEOGRAPHY